Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine + morphine + epinephrine
- Development stage
- Phase 4
- Lead developer
- Meir Medical Center
- Modality
- Small Molecules
- Administration
- Intrathecal, Local Infiltration
01
Overview
This multimodal analgesic regimen, utilized by Meir Medical Center, is designed for postoperative pain management in patients undergoing total knee arthroplasty. The protocol involves a spinal block consisting of intrathecal heavy bupivacaine (Marcaine) and morphine, combined with a high-volume local anesthetic infiltration (LIA) of bupivacaine and adrenaline (epinephrine). Bupivacaine provides regional anesthesia by blocking voltage-gated sodium channels, preventing the conduction of pain signals. Morphine acts as an agonist at mu-opioid receptors in the spinal cord to provide extended analgesia. Epinephrine is included as a vasoconstrictor to prolong the local anesthetic effect and minimize systemic toxicity. This combination is being evaluated in Phase 4 clinical trials to compare its efficacy in pain reduction and physical therapy outcomes against general anesthesia.
- Other names
- bupivacaine + morphine + adrenalineHeavy Marcainespinal blockMeir Medical Center spinal block protocol
02
Targets
ADRA2A (α2A)ADRB1 (β1)β-AR (Beta-adrenergic receptor family)MOR (Mu opioid receptor)ADRA1A (α1A)ADRB2 (β2)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on bupivacaine + morphine + epinephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine + morphine + epinephrine.